Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ACRT about to move to new highs -- Ignore unavailable to you. Want to Upgrade?

To: F. Lynn who wrote (3806)	3/19/1998 1:17:00 AM
From: Andrew Q. Viet	Respond to of 7054

It is highly valid. Glaxo got the delivery process. Is the Electronic Transaction a delivery process, yes it is. You are absolutely wrong man. the patent was granted, so it's enforceable. Of course someone could challange it in court, but by that time ACRT will have grown into a collosal entity.

To: F. Lynn who wrote (3806)	3/19/1998 1:22:00 AM
From: Goulds	Read Replies (2) \| Respond to of 7054

Flynn, there has not been prior use of the electronic TAD, and ACRT is taking all the right steps, such as their new 12 month TAD to make it a unique proprietary item. The court battle could be huge. Huge legal costs, and huge punitive damages to the transgressor, as well as those pesky royalties. To say nothing of bad press for Chase or Chemical Bank, just to name a few who will want to use the TAD process in the future. Much cheaper just to buy that little company at 50 or 100 dollars a share. Heck, there's not but 8 million shares all told...